A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 112, Issue 6, 2011, Pages 744-753

  Subramanian, Gayathri ^a   Cohen, Harold V ^a   Quek, Samuel Y P ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; PARATHYROID HORMONE[1-34];

ARTICLE; BONE REMODELING; DRUG EFFECT; HOMEOSTASIS; HUMAN; JAW OSTEONECROSIS; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; HOMEOSTASIS; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; TERIPARATIDE;

EID: 81355147542     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2011.04.020     Document Type: Article

References (102)

1. J. Marx Coming to grips with bone loss Science 305 2004 1420 1422 (Pubitemid 39167652)
2. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 2003 1115 1117 (Pubitemid 37064711)
3. R.E. Marx, Y. Sawatari, M. Fortin, and V. Broumand Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 2005 1567 1575 (Pubitemid 41525412)
4. T. Mavrokokki, A. Cheng, B. Stein, and A. Goss Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 2007 415 423 (Pubitemid 46343586)
5. P.P. Sedghizadeh, K. Stanley, M. Caligiuri, S. Hofkes, B. Lowry, and C.F. Shuler Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry J Am Dent Assoc 140 2009 61 66
6. D.H. Solomon, L. Rekedal, and S.M. Cadarette Osteoporosis treatments and adverse events Curr Opin Rheumatol 21 2009 363 368
7. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, and B. Mehrotra American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw2009 update Aust Endod J 35 2009 119 130
8. R.E. Marx, J.E. Cillo Jr, and J.J. Ulloa Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2007 2397 2410 (Pubitemid 350100982)
9. S. Koka, B.L. Clarke, S. Amin, M. Gertz, and S.L. Ruggiero Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient Int J Prosthodont 20 2007 115 122
10. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, and B. Mehrotra American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws2009 update J Oral Maxillofac Surg 67 2009 2 12
11. A. Cheung, and E. Seeman Teriparatide therapy for alendronate-associated osteonecrosis of the jaw N Engl J Med 363 2010 2473 2474
12. R.P. Harper, and E. Fung Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)] J Oral Maxillofac Surg 65 2007 573 580 (Pubitemid 46343587)
13. A.N. Lau, and J.D. Adachi Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy J Rheumatol 36 2009 1835 1837
14. J.J. Lee, S.J. Cheng, J.H. Jeng, C.P. Chiang, H.P. Lau, and S.H. Kok Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy Head Neck 2010 [10.1002/hed.21380]
15. P. Narongroeknawin, M.I. Danila, L.G. Humphreys Jr, A. Barasch, and J.R. Curtis Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report Spec Care Dentist 30 2010 77 82
16. K.Y. Tsai, C.S. Huang, G.M. Huang, and C.T. Yu More on the resolution of bisphosphonate-associated osteonecrosis of the jaw J Rheumatol 37 2010 675
17. R.D. Chapurlat Bone microdamage Osteoporos Int 20 2009 1033 1035
18. R.D. Chapurlat, and P.D. Delmas Bone microdamage: a clinical perspective Osteoporos Int 20 2009 1299 1308
19. K. Matsuo Cross-talk among bone cells Curr Opin Nephrol Hypertens 18 2009 292 297
20. K. Matsuo, and N. Irie Osteoclast-osteoblast communication Arch Biochem Biophys 473 2008 201 209
21. L.J. Raggatt, and N.C. Partridge Cellular and molecular mechanisms of bone remodeling J Biol Chem 285 2010 25103 25108
22. N.A. Sims, and J.H. Gooi Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption Semin Cell Dev Biol 19 2008 444 451
23. B. Noble Bone microdamage and cell apoptosis Eur Cells Mater 6 2003 46 55 Discussion (Pubitemid 38851420)
24. B. Noble Microdamage and apoptosis Eur J Morphol 42 2005 91 98 (Pubitemid 41074382)
25. B.S. Noble, N. Peet, H.Y. Stevens, A. Brabbs, J.R. Mosley, and G.C. Reilly Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone Am J Physiol, Cell Physiol 284 2003 C934 C943
26. G.Y. Rochefort, S. Pallu, and C.L. Benhamou Osteocyte: the unrecognized side of bone tissue Osteoporos Int 21 2010 1457 1469
27. E. Seeman Bone modeling and remodeling Crit Rev Eukaryot Gene Expr 19 2009 219 233
28. E. Seeman Osteocytesmartyrs for integrity of bone strength Osteoporos Int 17 2006 1443 1448
29. A. Lipton, R. Uzzo, R.J. Amato, G.K. Ellis, B. Hakimian, and G.D. Roodman The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors J Natl Compr Cancer Netw 7 Suppl 7 2009 S1 S29 Quiz S30
30. L.G. Raisz Pathogenesis of osteoporosis: concepts, conflicts, and prospects J Clin Invest 115 2005 3318 3325 (Pubitemid 43121814)
31. F. Milat, and K.W. Ng Is Wnt signalling the final common pathway leading to bone formation? Mol Cell Endocrinol 310 2009 52 62
32. S. Khosla Update on estrogens and the skeleton J Clin Endocrinol Metab 95 2010 3569 3577
33. B.F. Boyce, and L. Xing Biology of RANK, RANKL, and osteoprotegerin Arthritis Res Ther 9 Suppl 1 2007 S1
34. W.F. Li, S.X. Hou, B. Yu, M.M. Li, C. Ferec, and J.M. Chen Genetics of osteoporosis: accelerating pace in gene identification and validation Hum Genet 127 2010 249 285
35. R.S. Weinstein, R.L. Jilka, A.M. Parfitt, and S.C. Manolagas Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids Potential mechanisms of their deleterious effects on bone J Clin Invest 102 1998 274 282 (Pubitemid 28335186)
36. F.S. Wang, J.Y. Ko, L.H. Weng, D.W. Yeh, H.J. Ke, and S.L. Wu Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss Life Sci 85 2009 685 692
37. J.A. Kanis, F. Borgstrom, C. De Laet, H. Johansson, O. Johnell, and B. Jonsson Assessment of fracture risk Osteoporos Int 16 2005 581 589 (Pubitemid 40897454)
38. S. Barille-Nion, and R. Bataille New insights in myeloma-induced osteolysis Leuk Lymphoma 44 2003 1463 1467 (Pubitemid 36833957)
39. R. Bataille, D. Chappard, C. Marcelli, P. Dessauw, P. Baldet, and J. Sany Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma J Clin Invest 88 1991 62 66
40. G.D. Roodman Pathogenesis of myeloma bone disease Leukemia 23 2009 435 441
41. O. Sezer Myeloma bone disease Hematology 10 Suppl 1 2005 19 24 (Pubitemid 41825682)
42. S. Yaccoby, R.N. Pearse, C.L. Johnson, B. Barlogie, Y. Choi, and J. Epstein Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity Br J Haematol 116 2002 278 290 (Pubitemid 34156975)
43. H.S. McCarthy, and M.J. Marshall Dickkopf-1 as a potential therapeutic target in Paget's disease of bone Expert Opin Ther Targets 14 2010 221 230
44. M.J. Marshall, S.F. Evans, C.A. Sharp, D.E. Powell, H.S. McCarthy, and M.W. Davie Increased circulating Dickkopf-1 in Paget's disease of bone Clin Biochem 42 2009 965 969
45. M.T. Drake, B.L. Clarke, and S. Khosla Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 2008 1032 1045
46. M.T. Drake, and S.C. Cremers Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition Mol Interv 10 2010 141 152
47. P. Bergmann, J.J. Body, S. Boonen, Y. Boutsen, J.P. Devogelaer, and S. Goemaere Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club Int J Clin Pract 63 2009 19 26
48. L. Costa, and P.P. Major Effect of bisphosphonates on pain and quality of life in patients with bone metastases Nat Clin Pract Oncol 6 2009 163 174
49. L. Costa Bisphosphonates: reducing the risk of skeletal complications from bone metastasis Breast 16 Suppl 3 2007 S16 S20
50. M.M. McDonald, S. Dulai, C. Godfrey, N. Amanat, T. Sztynda, and D.G. Little Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling Bone 43 2008 653 662
51. T. Andersson, F. Agholme, P. Aspenberg, and P. Tengvall Surface immobilized zoledronate improves screw fixation in rat bone: a new method for the coating of metal implants J Mater Sci Mater Med 21 2010 3029 3037
52. C. Zhao, N. Irie, Y. Takada, K. Shimoda, T. Miyamoto, and T. Nishiwaki Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis Cell Metab 4 2006 111 121 (Pubitemid 44138718)
53. J. Li, T. Mashiba, and D.B. Burr Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage Calcif Tissue Int 69 2001 281 286 (Pubitemid 33140938)
54. G. Yin, Y. Bai, and E. Luo Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw Med Hypotheses 76 2011 347 349
55. P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, and M. Colombel Bisphosphonates inhibit angiogenesis in vitro and testosterone- stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 2002 6538 6544 (Pubitemid 35364119)
56. Y.D. Kwon, J.Y. Ohe, D.Y. Kim, D.J. Chung, and Y.D. Park Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res 22 2011 100 105
57. E. Canalis, A. Giustina, and J.P. Bilezikian Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 2007 905 916
58. S. Khosla, J.J. Westendorf, and M.J. Oursler Building bone to reverse osteoporosis and repair fractures J Clin Invest 118 2008 421 428 (Pubitemid 351206529)
59. M.R. Rubin, and J.P. Bilezikian Parathyroid hormone as an anabolic skeletal therapy Drugs 65 2005 2481 2498 (Pubitemid 41697316)
60. J.P. Bilezikian, M.R. Rubin, and J.S. Finkelstein Parathyroid hormone as an anabolic therapy for women and men J Endocrinol Invest 28 2005 41 49
61. A.L. Burshell, R. Moricke, R. Correa-Rotter, P. Chen, M.R. Warner, and G.P. Dalsky Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate Bone 46 2010 935 939
62. R. Eastell, P. Chen, K.G. Saag, A.L. Burshell, M. Wong, and M.R. Warner Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate Bone 46 2010 929 934
63. J.P. Vilardaga, G. Romero, P.A. Friedman, and T.J. Gardella Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm Cell Mol Life Sci 68 2010 1 13
64. J.E. Aubin, F. Liu, L. Malaval, and A.K. Gupta Osteoblast and chondroblast differentiation Bone 17 1995 77S 83S
65. J.P. Bilezikian Anabolic therapy for osteoporosis Int J Fertil Womens Med 50 2005 53 60 (Pubitemid 46638713)
66. M. Ellegaard, N.R. Jorgensen, and P. Schwarz Parathyroid hormone and bone healing Calcif Tissue Int 87 2010 1 13
67. R.L. Jilka Molecular and cellular mechanisms of the anabolic effect of intermittent PTH Bone 40 2007 1434 1446 (Pubitemid 46756429)
68. Y.L. Ma, R.L. Cain, D.L. Halladay, X. Yang, Q. Zeng, and R.R. Miles Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation Endocrinology 142 2001 4047 4054 (Pubitemid 32802678)
69. K. Nakahama Cellular communications in bone homeostasis and repair Cell Mol Life Sci 67 2010 4001 4009
70. R. Carpinteri, T. Porcelli, C. Mejia, I. Patelli, J.P. Bilezikian, and E. Canalis Glucocorticoid-induced osteoporosis and parathyroid hormone J Endocrinol Invest 33 2010 16 21
71. A. Sikon, and P. Batur Profile of teriparatide in the management of postmenopausal osteoporosis Int J Womens Health 2 2010 37 44
72. A.N. Lau, and J.D. Adachi Role of teriparatide in treatment of glucocorticoid-induced osteoporosis Ther Clin Risk Manag 6 2010 497 503
73. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guanabens, and C. Kasperk Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis J Bone Miner Res 26 2011 503 511
74. T. Hansen, M. Kunkel, A. Weber, and C. James-Kirkpatrick Osteonecrosis of the jaws in patients treated with bisphosphonateshistomorphologic analysis in comparison with infected osteoradionecrosis J Oral Pathol Med 35 2006 155 160
75. F. Dore, L. Filippi, M. Biasotto, S. Chiandussi, F. Cavalli, and R. Di Lenarda Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw J Nucl Med 50 2009 30 35
76. N. Raje, S.B. Woo, K. Hande, J.T. Yap, P.G. Richardson, and S. Vallet Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw Clin Cancer Res 14 2008 2387 2395 (Pubitemid 351551072)
77. F. Dore, and L. Filippi Bone Scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the Jaw J Nucl Med 50 2009 1385
78. S. Hoefert, I. Schmitz, A. Tannapfel, and H. Eufinger Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings Clin Oral Investig 14 2010 271 284
79. M.R. Allen Studying the role of microcracks in the pathophysiology of BRONJ Clin Oral Investig 13 2009 481 482 Author reply: 3-4
80. T. Mashiba, T. Tanizawa, Y. Takano, H.E. Takahashi, S. Mori, and H. Norimatsu A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1-34) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats Bone 17 1995 273S 278S
81. T. Van den Wyngaert, M.T. Huizing, E. Fossion, and J.B. Vermorken Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw Clin Nucl Med 36 2010 17 20
82. M. Catto A histological study of avascular necrosis of the femoral head after transcervical fracture J Bone Joint Surg Br 47 1965 749 776
83. P.K. Palaska, V. Cartsos, and A.I. Zavras Bisphosphonates and time to osteonecrosis development Oncologist 14 2009 1154 1166
84. C.T. Chiu, W.F. Chiang, C.Y. Chuang, and S.W. Chang Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jawa serial case analysis J Oral Maxillofac Surg 68 2010 1055 1063
85. N.A. Greggio, M. Pillon, E. Varotto, A. Zanin, E. Talenti, and A.C. Palozzo Short-term bisphosphonate therapy could ameliorate osteonecrosis: a complication in childhood hematologic malignancies Case Report Med 2010 2010 206132
86. R.S. Kotecha, N. Powers, S.J. Lee, K.J. Murray, T. Carter, and C. Cole Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL) Pediatr Blood Cancer 54 2010 934 940
87. J.D. Ringe, and J.J. Body A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover Clin Exp Rheumatol 25 2007 766 774 (Pubitemid 350284855)
88. J.D. Ringe, A. Dorst, and H. Faber Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate Osteoporos Int 16 2005 2063 2068 (Pubitemid 41790928)
89. R. von Moos, F. Strasser, S. Gillessen, and K. Zaugg Metastatic bone pain: treatment options with an emphasis on bisphosphonates Support Care Cancer 16 2008 1105 1115
90. K.H. Taylor, L.S. Middlefell, and K.D. Mizen Osteonecrosis of the jaws induced by anti-RANK ligand therapy Br J Oral Maxillofac Surg 48 2010 221 223
91. K. Froelich, A. Radeloff, C. Kohler, R. Mlynski, J. Muller, and R. Hagen Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study Eur Arch Otorhinolaryngol 268 2011 1219 1225
92. N.M. Le Douarin, and C. Kalcheim The neural crest 2nd ed. 1999 Cambridge University Press UK
93. D. Stefanik, J. Sarin, T. Lam, L. Levin, P.S. Leboy, and S.O. Akintoye Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate Oral Dis 14 2008 465 471 (Pubitemid 351841723)
94. F. Wehrhan, P. Hyckel, K. Amann, J. Ries, P. Stockmann, and K. Schlegel Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment Oral Dis 17 2011 433 442
95. D. Khadka, T. Luo, and T.D. Sargent Msx1 and Msx2 have shared essential functions in neural crest but may be dispensable in epidermis and axis formation in Xenopus Int J Dev Biol 50 2006 499 502
96. L. Song, Y. Li, K. Wang, Y.Z. Wang, A. Molotkov, and L. Gao Lrp6-mediated canonical Wnt signaling is required for lip formation and fusion Development 136 2009 3161 3171
97. K.A. Mensah, J. Li, and E.M. Schwarz The emerging field of osteoimmunology Immunol Res 45 2009 100 113
98. N.H. Li, Y. Ouchi, Y. Okamoto, A. Masuyama, M. Kaneki, and A. Futami Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells Biochem Biophys Res Commun 179 1991 236 242
99. A.J. Littlewood, J. Russell, G.R. Harvey, D.E. Hughes, R.G. Russell, and M. Gowen The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro Endocrinology 129 1991 1513 1520
100. S.K. Kumar, A. Gorur, C. Schaudinn, C.F. Shuler, J.W. Costerton, and P.P. Sedghizadeh The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy Curr Osteoporos Rep 8 2010 40 48
101. P.P. Sedghizadeh, S.K. Kumar, A. Gorur, C. Schaudinn, C.F. Shuler, and J.W. Costerton Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy J Oral Maxillofac Surg 66 2008 767 775 (Pubitemid 351381805)
102. I.R. Reid, M.J. Bolland, and A.B. Grey Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 2007 318 320 (Pubitemid 47199147)